Repligen (NASDAQ:RGEN) Upgraded to Hold at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

A number of other equities analysts have also commented on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.20.

Repligen Trading Up 4.8 %

RGEN traded up $6.85 during trading hours on Friday, reaching $149.90. 504,733 shares of the company’s stock traded hands, compared to its average volume of 401,016. The firm has a 50-day moving average price of $144.96 and a 200 day moving average price of $142.20. The firm has a market capitalization of $8.40 billion, a PE ratio of -405.12, a PEG ratio of 4.64 and a beta of 0.97. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.23 earnings per share. As a group, sell-side analysts predict that Repligen will post 1.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank increased its position in shares of Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after buying an additional 89 shares during the last quarter. MML Investors Services LLC increased its position in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 89 shares in the last quarter. GAMMA Investing LLC raised its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares during the last quarter. Finally, Ballentine Partners LLC boosted its holdings in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 105 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.